Double Bond Pharmaceutical reduced losses in 2024 while advancing SI-053 toward clinical trials, securing new financing, and optimizing manufacturing. Liquidity is expected to last until Q3 2025, with further funding planned from grants and partnerships.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.